Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 1, 1997, Pages 597-603

  Lidow, Michael S ^a,b   Elsworth, John D ^a   Goldman Rakic, Patricia S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; HALOPERIDOL; INDOLE DERIVATIVE; MESSENGER RNA; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; REMOXIPRIDE; RIBONUCLEASE; RISPERIDONE; TIAPRIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; DOPAMINE; DOWN-REGULATION; GENE EXPRESSION REGULATION; MACACA MULATTA; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D5; RNA, MESSENGER;

EID: 0030924276     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. ANDREASEN, N. C. AND OLSEN, S.: Negative versus positive schizophrenia. Ach. Gen. Psychiatr. 39: 789-794, 1982.
2. ANGULO, J. A., COIRINI, H., LEDOUX, M. AND SCHUMACHER, M.: Regulation by doparninergic neurotransmission of dopamine D2 mRNA and receptor levels in the neostriatum and nucleus accumbens of the rat. Mol. Brain Res. 11: 161-166, 1991.
3. ASHBY, C. R., HITZMANN, R., RUBINSTEIN, J. E. AND WANG, R. Y.: One year treatment with haloperidol or clozapine fails to alter neostriatal D1- and D2-dopamine sensitivity in the rat. Brain Res. 493: 194-197, 1989.
4. BACOPOULOS, N. C., SPOKES, E. G., BIRD, E. D. AND ROTH, R. H.: Antipsychotic drug action in schizophrenic patients: Effect on cortical dopamine metabolism after long-term treatment. Life. Sci. 205: 1405-1407, 1979.
5. BERMAN, K. F., ZEK, R. F. AND WEINBERGER, D. R.: Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention and mental effort. Arch. Gen. Psychiatry 43: 126-135, 1986.
6. BILDER, R. M., MUKHERJEE, S., RIEDER, R. O. AND PANDURANGI, A. K.: Symptomatic and neuropsychological components of defect states. Schizophr. Bull. 11: 409-419, 1985.
7. BURMA, O. J. S., Roos, R. A. C., BRUYN, G. W., KEMP, B. AND VAN DER VELDE, E. A.: Tiapride in the treatment of tardive dyskinesia. Acta Neurol. Scand. 65: 38-44, 1982.
8. CLASSEN, W. AND LAUX, G.: Sensomotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupentixol, or clozapine. Pharmacopsychiatry 21: 295-297, 1988.
9. CREESE, I., BURT, D. R. AND SNYDER, S. H.: Dopamine receptors and average clinical doses. Science (Wash. DC) 194: 481-483, 1976.
10. CREESE, I. AND HESS, E. S.: Biochemical characteristics of D1 dopamine receptors: Relationship to behavior and schizophrenia. Clin. Neuropharmacol. 9: suppl. 4, 14-16, 1986.
11. CREESE, I., VANTOL, H. H. M., RIVA, M. AND CIVELLI, O.: Lack of effect of chronic dopamine receptor blockade on D2 dopamine receptor mRNA levels. Euro. J. Pharmacol. 183: 1404-1410, 1990.
12. DAVIDSON. M., HARVEY, P. D., BERGMAN, R. L., POWCHIK, P., KAMINSKY, R., LOSONCZY, M. F. AND DAVIS, K.: Effects of the D1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch. Gen. Psychiatry 47: 190-191, 1990.
13. DAVIES, K. L., KAHN, K. S., Ko, G. AND DAVIDSON, M.: Dopamine in schizophrenia. Am. J. Psychiatry 148: 1474-1486, 1991.
14. DE BOER, J. A., VAN MEGEN, H. J. G. M., FLEISCHHACKER, W. W., LOUWERENS, J. W., SAAP, B. R., WESTENBERG, H. G. M., BURROWS, G. D. AND SRIVASTAVA, O. N.: Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. Psychopharmacoly 121: 317-322, 1995.
15. EGAN, M. F., HURD, Y., HYDE, T. M., WEINBERGER, D. R., WYATT, R. J. AND KLEINMAN, J. E.: Alterations in mRNA levels of D2 receptors and neuropeptides in neostriatonigral and stiatopalidal neurons of rats with neurolepticinduced dyskinesias. Synapse 18: 178-189, 1994.
16. EGCERS, C., ROTHENBERGER, A. AND BERGHANS, U.: Clinical and neurobiological findings in children suffering from disease following treatment with tiapride. Eur. Arch. Psychiatry Neurol. Sci. 237: 223-229, 1988.
17. ESSIG, E. C. AND KILPATRICK, I. C.: Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology 104: 194-200, 1991.
18. FISHBURN, C. S., DAVID, C., CARMON, S. AND FUCHS, S.: The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett. 339: 63-66, 1994.
19. Fox, C. A., MANSOUR, A. AND WATSON, S. J.: The effects of haloperidol on dopamine receptor gene expression. Exp. Neurol. 130: 288-303, 1994.
20. GOLDMAN-RAKIC, P. S.: Circuitry of primate prefrontal cortex and regulation of behavior by representation memory. In Handbook of Physiology, Vol. V, The Nervous System, Higher Functions of the Brain, ed., by F. Plum, pp. 373-417, Am. Physiol. Soc., Bethesda, MD, 1987.
21. GOLDMAN-RAKIC, P. S.: Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory. In Psychopathology and the Brain, ed. by B. J. Carroll and E. J. Barrett, pp. 1-23, Raven Press, New York, 1991.
22. GOLDMAN-RAKIC, P. S., LIDOW, M. S., SMILEY, J. F. AND WILLIAMS, M. S.: The anatomy of dopamine in monkey and human prefrontal cortex. J. Neural Trans.: suppl. 36, 163-177, 1992.
23. GRACE, A. A.: Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia Neuroscience 41: 1-24, 1991.
24. HESS, E. J., NORMAN, A. B. AND CREESE, I.: Chronic treatment with dopamine receptor antagonists: Behavioral and pharmacologie effects on D1 and D2 dopamine receptors. J. Neurosci. 8: 2361-2370, 1988.
25. HINDMARCH, I.: Neuroleptic induced deficit syndrome: Behavioral toxicity of neuroleptics in man. In Schizophrenia: Exploring the Spectrum of Psychosis, ed. by J. Ancill, S. Holliday and J. Higenbottam. pp. 305-320. John Willey and Sons, New York, 1994.
26. HYMAN, S. E. AND ARANA, G. W.: Handbook of Psychiatric Drug Therapy. Little, Brown, Boston, 1987.
27. JANSSEN, P. A. J., NIEMEGEERS, C. J. E., AWOUTERS, F., SCHELLWKENS, K. H. L., MEGENS, A. A. H. P. AND MEERT, T. F.: Pharmacology of risperidone (R-64-766). A new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 344: 685-693, 1988.
28. JIANG, L. H., KASSER, R. J., ALTAR, C. A. AND WANG, R. Y.: One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of cauda-putamen neurons to dopamine D1 and D2 receptor agonists. J. Pharmacol. Exp. Ther. 253: 1198-1205, 1990.
29. JOHNSTONE, E. C., CROW, T. J., FRITH, C. D., STEVENS, M., KREEL, L. AND HUSBAND, J.: The dementia of dementia praecox. Acta Psychiatr. Scand. 57: 305-324, 1978.
30. KAHLE, J., CLEMMESEN, L., HANSEN, L., ANDERSEN, M., ANDERSEN, J., FENSBO, C., SLOTH-NIELSEN, M., SKRUMSAGER, B. K., LUBIN, H. AND GERLACH, J.: NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121: 328-329, 1995.
31. KING, D. J.: The effect of neuroleptics on cognitive and psychomotor function. Br J. Psychiatry 157: 799-811, 1990.
32. KOPP, J., LINDEFORS, N., BRENE, S., HALL, H., PERSSON, H. AND SEDVALL, G.: Effect of raclopride on dopamine D2 receptor mRNA expression in rat brain. Neuroscience 47: 771-779, 1992.
33. LAPPALAINEN, J., HIETALA, J., KOULU, M., SEPPALA, T., SJOHOLM, B. AND SYVALAHTI, E.: J. Pharmacol. Chronic treatment with SCH23390 and haloperidol: Effects on dopaminergic and serotonergic mechanism in rat brain. Exp. Ther. 252: 845-852, 1990.
34. LIDOW, M. S. AND GOLDMAN-RAKIC, P. S.: A common action of clozapine, haloperidol and remoxipride on D1- and D2-dopamine receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 91: 4353-4356, 1994.
35. LIDOW, M. S., WANG, F., CAO, Y. AND GOLDMAN-RAKIC, P. S.: Layer V neurons bear the majority of mRNAs encoding D1, D2, D3, D4 and D5 dopamine receptors in the primate prefrontal cortex. Synapse. In press.
36. LINDENMAYER, J. P.: New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. 91: 15-19, 1995.
37. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDAL, R. J.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
38. MACKENZIE, R. G. AND ZIGMOND, M. J.: Chronic neuroleptic treatment increases D2 but not D1 receptors in rat neostriatum. Eur. J. Pharm. 113: 159-165, 1985.
39. MATSUNAGA, T., OHARA, K., NATSUKARI, N. AND EUJITA, M.: Dopamine D2 receptor mRNA level in rat neostriatum after chronic haloperidol treatment. Neuro. sci. Res. 12: 440-445, 1991.
40. MCKENNA, P. J., LUND, C. E. AND MORTIMER, A. M.: Negative symptoms: Relationship to other schizophrenic symptoms classes. Brit. J. Psychiatry 155: 104-107, 1989.
41. MELTZER, H. Y. AND ZUREICK, J.: Negative symptoms in schizophrenia: A target for new drug development. In Clinical Pharmacology in Psychiatry, ed. by S. G. Dahl, and L. F. Gram. pp. 68-77. Springer, Berlin, 1989.
42. MOLLER, H-J.: Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur. Neuropsy. chopharmacol. 3: 1-11, 1993.
43. MOORE, N. A., TUPPER, D. E. AND HOTTEN, T. M.: The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. Drugs of the Future. 19: 114-117, 1994.
44. O'DELL, S. G., HOSTE, G. J., WlDMARK, C. B., SHAPIRO, R. M., POTKIN, S. G. AND MARSHALL, J. F.: Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146-153, 1990.
45. PARSONS, L. H., SCHAD, C. A. AND JUSTICE, J. B.: Co-administration of the antagonist pimozide inhibits upregulation of dopamine release and uptake induced by repeated cocaine. J. Neurochem. 60: 376-379, 1993.
46. PFLUG, B., BARTELS, M., BANER, H., BUNSE, J., GALLHOFER, B., HAAS, S., KONZOW, W. T. H., LKIESER, E., KUFFERLE, B., STEIN, D., STEINBERG, K. A. AND WEISEL-MANN, G.: A double-blind multicentre study comparing remoxipride controlled release formulation with haloperidol in schizophrenia. Acta Psychiatr. Scand. 82: suppl. 358, 142-146, 1990.
47. Physicians' Desk Reference, 50th edition. Medical Economics Company Inc., Oradell, NJ, 1996.
48. RUPNIAK, N. M. J., HALL, M. D., MANN, S., FLEMINGER, S., KILPATRICK, G., JENNER, P. AND MARSDEN, C. D.: Chronic treatment with clozapine, unlike haloperidol, does not induce changes in neostriatal D2 receptor function in rat. Biochem. Pharmacol. 34: 2755-2763, 1985.
49. SCATTON, B.: Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur. J. Pharmacol. 46: 363-369, 1977.
50. SEDVALL, G. AND FARDE, L.: Dopamine receptors in schizophrenia. Lancet 347: 264, 1996.
51. SEE, R. E., TOGA, A. W. AND ELLISON, G.: Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rat. J. Neural Trans. 82: 93-109, 1990.
52. SEEMAN, P., CHAN-WANG, M., TEDESCO, J. AND WANG, K.: Brain receptors for antipsychotic drugs and dopamine: Direct binding assay. Proc. Natl. Acad. Sci. U.S.A. 72: 4376-4380, 1975.
53. SEEMAN, P., NIZNIK, H. B., GUAN, H. C., BOOTH, G. AND ULPIAN, C.: Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntingdon diseased brain. Proc. Natl. Acad. Sci. U.S.A. 86: 10156-10160, 1989.
54. SEEMAN, P.: Dopamine receptor sequences. Therapeutic levels of neuroleptic occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7: 261-284, 1992.
55. SELEMON, L. D., RAJKOWSKA, G. AND GOLDMAN-RAKIC, P. S.: Abnormally high neuronal density in two widespread areas of the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatr. 52: 808-818, 1995.
56. SHENTON, M. E., KIKINS, R. D., JOLESZ, F. A., POLLAC, S. D., LEMAY, M., WIBLE, C. G., HOKAMA, H., MARTIN, J., MATCALF, D., COLEMAN, M. AND MCGARLEY, R. W.: Abnormalities of the left temporal lobe and thought disorder in schizophrenia. New Engl. J. Med. 327: 604-612, 1992.
57. STAFFORD, J. E., JACKSON, L. S., FORREST, T. J., BARROW, A. AND PALMER, R. F.: Haloperidol pharmacokinetics: A preliminary study in rhesus monkeys using a new radioimmunoassay procedure. J. Pharmacol. Methods. 6: 261-279, 1981.
58. STRANGE, P. G.: D1/D2 dopamine receptor interaction at the biochemical level. Trends Pharmacol. Sci. 12: 48-49, 1991.
59. TAYLOR, M. A. AND ABRAMS, R.: Cognitive impairment in schizophrenia. Am. J. Psychiatr. 141: 196-201, 1984.
60. TOMER, R. AND FLOR-HENDRY, P.: Neuroleptics reverse attention asymmetries in schizophrenic patients. Biolog. Psychiatr. 23: 852-860, 1989.
61. WALKER, A. E.: A cytoarchitectural study of the prefrontal area of the macaque monkey. J. Comp. Neurol. 73: 59-86, 1940.
62. WEINBERGER, D. R.; Schizophrenia and the frontal lobe. Trends Neurosci. 11: 367-370, 1988.
63. WILLIAMS, G. V. AND GOLDMAN-RAKIC, P. S.: Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature (Lond.) 376: 572-575, 1995.
64. XU, S., MONSMA, F. J., SIBLEY, D. R. AND CREESE, L: Regulation of D1 and D2 dopamine receptor MRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci. 50: 283-396, 1991.